Bavarian Nordic delivers Imvamune to U.S.

Four years after creating Project Bioshield, the U.S. has received the program's first successful vaccine. Bavarian Nordic has delivered one million doses of its smallpox vaccine Imvamune to the U.S. Strategic National Stockpile. The doses will be stored in case of a bioterrorism attack. The U.S.'s contract guarantees 20 million doses of the vaccine, with an option to obtain an additional 60 million. The delivery marks Bavarian Nordic's first U.S. sale. "We look forward to continuing that partnership through other contracts with the US government," said CEO and president Anders Hedegaard to Pharma Letter. The company has not released the financial details of their contract. Imvamune uses a non-replicating strain of vaccinia virus, which should eliminate secondary infection via physical or sexual contact. Article

Related Articles:
Smallpox vaccinia virus spread by physical contact
Researchers test side effects of new smallpox vaccine